Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer
Pancreatology · 2025
DOI: 10.1016/j.pan.2025.03.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2025. Verfasst von Sen Lei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Su…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neutrophils, Apolipoprotein A-I. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Identification of a biomarker predicting chemotherapy efficacy in patients with advanced pancreatic cancer (APC) is urgently needed. This study aimed to determine the association between the neutrophil-to-apolipoprotein A1 ratio (NEAPO) and chemotherapy efficacy in APC patients. METHODS: This retrospective study involved 236 APC patients who underwent first-line chemotherapy, including FOLFIRINOX (FFX), nab-paclitaxel plus gemcitabine (AG), or SOXIRI. Receiver operating characteristic curve analysis was performed to determine the optimal cutoff value of NEAPO, and patients were divided into low and high NEAPO groups. Kaplan-Meier curves and Cox regression analyses were used to evaluate the effect of NEAPO on overall survival (OS) and progression-free survival (PFS). RESULTS: The optimal cutoff of NEAPO was 4.69. High NEAPO levels were associated with shorter OS (p = 0.046) and PFS (p = 0.001). In the NEAPO low subgroup, the median PFS of SOXIRI was longer than that in AG group (7.2 months vs. 5.5 months, p = 0.029), with no significant difference of PFS between SOXIRI and FFX (p = 0.691). There is a trend but not significant difference in PFS between AG and FFX (p = 0.096). The proportion of disease control rate (DCR) was higher in SOXIRI group. In the NEAPO high subgroup, there was no significant difference in PFS among the three regimens, while the DCR was higher in AG group. CONCLUSIONS: NEAPO levels were significantly associated with OS, PFS and treatment response in APC patients who underwent chemotherapy and might be a useful biomarker for predicting chemotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
- Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, PR China.
- Department of Medical Imaging, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
- Department of Medical Imaging, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China. Electronic add…
Zitieren
APA
Lei, S., Mao, Y., Qin, T., Zhou, J., Mai, Z., Xu, J., Zhang, R., & Yang, Q. (2025). Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer. Pancreatology. https://doi.org/10.1016/j.pan.2025.03.004
Vancouver
Lei S, Mao Y, Qin T, Zhou J, Mai Z, Xu J, et al. Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer. Pancreatology. 2025. doi:10.1016/j.pan.2025.03.004
BibTeX
@article{Lei2025,
author = {Lei, Sen and Mao, Yize and Qin, Tao and Zhou, Jianyao and Mai, Zhijun and Xu, Jiahui and Zhang, Rong and Yang, Qiuxia},
title = {Neutrophil-to-apolipoprotein A1 ratio predicted the efficiency of chemotherapy in advanced pancreatic cancer},
journal = {Pancreatology},
year = {2025},
doi = {10.1016/j.pan.2025.03.004}
}
EUVIMED